You are here

Home » Content

STEM CELLS IN NEUROPHARMACOLOGY: AN OVERVIEW

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
Stem cells have remarkable potential to develop into many different cell types in the body. Stem cells are the unspecialized cells capable of renewing themselves through cell division and under certain pathological or experimental conditions, they can be induced to become tissue or organ-specific cells with special functions. Stem cell–based approaches have received much hype as potential treatments for neurodegenerative disorders. In chronic cases, there is either a selective loss of specific cell population, such as dopaminergic neurons in Parkinson disease, inflammatory de-myelination of neurons in Multiple sclerosis, degeneration of motor neurons in ALS, widespread degeneration of many types of neuron, such as occurs in Alzheimer disease over a period of several years. Stem cell–based approaches could be used therapeutically to restore functions in neurodegenerative disorders. Transplantation of stem cells or their derivatives in animal models of neurodegenerative disorders can improve functions by replacing the lost neurons and glial cells, by mediating remyelination or trophic actions and modulation of inflammation. Endogenous neural stem cells are also potential therapeutic targets because they produce neurons and glial cells in response to injury and could be affected by the degenerative process.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastrmx_160852_2_pp_22-32.pdf
  • 1
22-32
  • English

REFERENCES

References: 

1. Stem cells: What they are and what
they do? Last updated 13/3/2012
http://www.mayoclinic.com/health/ste
m-cells/CA00081
2. Multiple Sclerosis. Last updated
2/6/2012http://www.mssociety.org.uk
STUTI et al., ARPB, 2012; Vol 2 (1) ISSN 2250-0774
(Review Article)
www.arpb.info Page 31
3. O. Lindvall, Z. Kokaia. Stem cells for
the treatment of neurological disease,
Nature Med. 441: 1-2 (2006).
4. M. Windrem, et al. Fetal and adult
human oligodendrocyte progenitor cell
isolates myelinate the congenitally
dysmyelinated brain, Nature Med. 10:
93–97 (2004).
5. S. Back, et al. Hyaluronan accumulates
in demyelinated lesions and inhibits
oligodendrocyte progenitor maturation,
Nature Med. 11: 966–972 (2005).
6. S. Pluchino, et al. Injection of adult
neurospheres induces recovery in a
chronic model of multiple sclerosis,
Nature 422: 688–694 (2003).
7. S. Pluchino, et al. Neurosphere-derived
multipotent precursors promote
neuroprotection by an
immunomodulatory mechanism,
Nature 436: 266–271 (2005).
8. C. McDonald, C. Siatskas. The
emergence of amnion epithelial stem
cells for the treatment of Multiple
Sclerosis, Review of inflammation and
regeneration 31 (3): 256-262 (2011).
9. S. Goldman. Stem and progenitor cellbased
therapy of the human central
nervous system, Review in Nat.
Biotechnol. 23 (7): 863-865 (2005).
10. S. Pluchino, et al. Neurosphere-derived
multipotent precursors promote
neuroprotection by an
immunomodulatory mechanism,
Nature. 436 (7048): 266–271 (2005).
11. O. Lindvall, A. Björklund. Cell therapy
in Parkinson’s disease, NeuroRx. 1 (4):
382–393 (2004).
12. O. Isacson, L. M. Björklund, J. M.
Schumacher. Toward full restoration of
synaptic and terminal function of the
dopaminergic system in Parkinson’s
disease by stems cells, Ann Neurol.
253 (suppl 3): S135– S146; discussion
S146–S138 (2003).
13. I. Mendez, et al. Cell type analysis of
functional fetal dopamine cell
suspension transplants in the striatum
and substantia nigra of patients with
Parkinson’s disease, Brain. 128( 7):
1498–1510 (2005).
14. O. Lindvall, Z. Kokaia. Stem cells in
human neurodegenerative disorderstime
for clinical translation? J Clin
Invest. 120 (1): 30-31 (2010).
15. N. S. Roy, C. Cleren, S. K. Singh, L.
Yang, M. F. Beal, S. A. Goldman.
Functional engraftment of human ES
cell-derived dopaminergic neurons
enriched by coculture with telomeraseimmortalized
midbrain astrocytes, Nat
Med. 12 (11): 1259–1268 (2006).
16. A. E. Lang, J. A. Obeso. Challenges in
Parkinson’s disease: restoration of the
nigrostriatal dopamine system is not
enough, Lancet Neurol. 3 (5): 309–316
(2004).
17. C. W. Olanow, K. Kieburtz, A. H.
Schapira. Why have we failed to
achieve neuroprotection in Parkinson’s
STUTI et al., ARPB, 2012; Vol 2 (1) ISSN 2250-0774
(Review Article)
www.arpb.info Page 32
disease? Ann Neurol. 64 (2): S101–
S110 (2008).
18. S. Behrstock, et al. Human neural
progenitors deliver glial cell linederived
neurotrophic factor to
parkinsonian rodents and aged
primates, Gene Ther. 13 (5): 379–388
(2006).
19. I. Park, et al. Disease-specific induced
pluripotent stem (iPS) cells, Cell
134(5): 877–886 (2008).
20. E. Hedlund, M. P. Hefferan, M.
Marsala and O. Isacson. Cell therapy
and stem cells in animal models of
motor neuron disorders, Eur. J.
Neurosci., 26: 1721-1737 (2007).
21. J. M. Harper, et al. Axonal growth of
embryonic stem cell-derived
motoneurons in vitro and in
motoneuron- injured adult rats, Proc
Natl Acad Sci U S A. 101 (18): 7123–
7128 (2004).
22. D. M. Deshpande, et al. Recovery from
paralysis in adult rats using embryonic
stem cells, Ann Neurol. 60 (1): 32–44
(2006).
23. D. A. Kerr, et al. Human embryonic
germ cell derivatives facilitate motor
recovery of rats with diffuse motor
neuron injury, J Neurosci. 23 (12):
5131–5140 (2003).
24. L. Xu, et al. Human neural stem cell
grafts ameliorate motor neuron disease
in SOD-1 transgenic rats,
Transplantation. 82 (7): 865–875
(2006).
25. L. Xu, D. K. Ryugo, T. Pongstaporn,
K. Johe, V. E. Koliatsos. Human neural
stem cell grafts in the spinal cord of
SOD1 transgenic rats: differentiation
and structural integration into the
segmental motor circuitry, J Comp
Neurol. 514 (4): 297–309 (2009).
26. M. Suzuki, et al. Direct muscle
delivery of GDNF with human
mesenchymal stem cells improves
motor neuron survival and function in
a rat model of familial ALS, Mol Ther.
16 (12): 2002–2010 (2008).
27. H. P. Rang, M. M. Dale, J. M. Ritter,
R. J. Flower. Rang and dale’s
Pharmacology, Neurodegenerative
disease, Elsevier, U.K, 2007, pp. 514-
515.
28. E. Dantuma, S. Merchant, K. Sugaya.
Stem cells for the treatment of
neurodegenerative diseases, Stem Cell
Research & Therapy 1 (37): 2010
29. L. Qiang, R. Fujita, T. Yamashita, S.
Angulo, H. Rhinn, D. Rhee, C. Doege,
L. Chau, L. Aubry, B. William, et al.
Directed Conversion of Alzheimer's
Disease Patient Skin Fibroblasts Into
Functional Neurons, Cell 5 146 (3):
359 – 371 (2011).

Thank you for copying data from http://www.arastirmax.com